Table 3. Relationship between PKCδ mRNA and both overall survival and disease-free interval in breast cancer.
| Univariate analysis |
Multivariate analysis
|
|||
|---|---|---|---|---|
| Factors | P-value | P-value | RR | 95% CI |
| Overall survival | ||||
| Tumour size (continuous) | 0.015 | 0.172 | 1.206 | 0.922–1.578 |
| Nodal categorya | 0.002 | 0.037 | 1.996 | 1.044–3.816 |
| Tumour grade (3 vs 1 and 2) | 0.009 | 0.079 | 2.796 | 0.887–8.821 |
| ER status | 0.615 | NSb | ||
| PKCδ (continuous) | 0.004 | 0.038 | 1.157 | 1.008–1.328 |
| Disease-free interval | ||||
| Tumour size (continuous) | 0.161 | NSb | ||
| Nodal categorya | 0.001 | 0.021 | 1.871 | 1.098–3.189 |
| Tumour grade (3 vs 1 and 2) | 0.010 | 0.074 | 2.370 | 0.919–6.110 |
| ER status | 0.977 | NSb | ||
| PKCδ (continuous) | 0.074 | 0.052 | 1.125 | 0.999–1.268 |
CI=confidence interval; PKC=protein kinase C; RR=relative risk.
a
Nodal status divided into categories: 0, 1–3 and >3 involved nodes.
b
NS, not significant (P>0.05).